. 2022 Aug 23;37(1):2265–2282. doi: 10.1080/14756366.2022.2104841

Table 5.

Inhibitory activities of thiazolyl-pyrazoline derivatives (7a–7d, 10a–10d and 13a–13f) against cancerous and normal lung cells. Values represent the mean IC₅₀ values (µM) ± SEM (n = 3) for each drug. Compared IC₅₀s; a compounds versus gefitinib and b compounds versus Vandetanib.

Compound	IC₅₀ (µM) ± SEM
Compound	A549	H441	WI-38
7a	22.5 ± 1.2^a ns, ^b***	38.4 ± 2.3^a*, ^b*	88.2 ± 4.2 ^a*, ^b*
7b	12.0 ± 0.4^a*, ^b*	26.5 ± 1.1^a*, ^b*	60.6 ± 3.1^a*, ^b*
7c	>100	>100	>100
7d	20.2 ± 2.0^a ns, ^b***	29.1 ± 3.5^a*, ^b*	40.1 ± 2.7^a, ^b**
10a	49.1 ± 3.2^a*, ^b*	>100	>100
10b	4.2 ± 0.8^a***, ^bns	4.8 ± 0.1^a*, ^bns	72.4 ± 7.2^a*, ^b*
10c	23.5 ± 1.3^a ns, ^b***	45.2 ± 2.3^a*, ^b*	>100
10d	2.9 ± 0.2^a***, ^bns	3.8 ± 0.5^a*, ^bns	51.4 ± 3.5^a*, ^b*
13a	>100	94.4 ± 5.5^a*, ^b*	>100
13b	59.1 ± 3.2^a*, ^b*	24.2 ± 1.8^a*, ^b*	>100
13c	46.3 ± 2.5^a*, ^b*	33.5 ± 3.9^a*, ^b*	91.4 ± 8.9^a*, ^b*
13d	57.1 ± 4.1^a*, ^b*	21.7 ± 1.3^a*, ^b*	64.2 ± 2.8^a*, ^b*
13e	19.1 ± 1.3^a, ^b**	15.2 ± 3.6^a*, ^b*	87.0 ± 4.2^a*, ^b*
13f	13.7 ± 2.2^a, ^b*	24.8 ± 1.4^a*, ^b*	>100
Gefitinib	22.3 ± 1.4	7.1 ± 1.3	35.1 ± 2.0
Vandetanib	3.4 ± 1.0	3.9 ± 0.8	8.6 ± 0.4

*p < 0.05, **p < 0.01, ***p < 0.001 and ns = non-significant.